Penumbra Reports $374.8 Million Revenue in Q1 2026, 15.6% Increase Year-Over-Year

Penumbra, Inc. reported a revenue of $374.8 million for the first quarter of 2026, marking a 15.6% increase from $324.1 million in the same period of 2025. The growth was primarily driven by increased sales in both thrombectomy and embolization product lines, with thrombectomy sales rising to $253.9 million, a 12.1% increase, and embolization and access products growing by 23.8% to $120.8 million. Despite the revenue growth, the company experienced a decline in net income, which fell to $32.6 million from $39.2 million year-over-year, resulting in a diluted earnings per share of $0.82 compared to $1.00 in the prior year.

The company's operating expenses increased significantly, totaling $215.2 million, up from $175.5 million in the previous year, largely due to a 25.6% rise in sales, general, and administrative expenses, which reached $192.8 million. This increase was attributed to higher personnel costs and acquisition-related expenses linked to the pending merger with Boston Scientific Corporation, which is valued at approximately $14.5 billion. The merger agreement, announced on January 14, 2026, allows shareholders to choose between cash or stock in the acquiring company, with the transaction expected to close by the end of 2026, pending regulatory approvals.

Operationally, Penumbra's total assets increased to $1.9 billion as of March 31, 2026, up from $1.8 billion at the end of 2025. The company reported a cash and cash equivalents balance of $241.3 million, alongside $374.4 million in marketable investments. The increase in cash flow from operating activities was notable, with $87.0 million generated in the first quarter of 2026 compared to $49.0 million in the same period last year. This was supported by a decrease in accounts receivable and an increase in accrued liabilities.

Penumbra's international sales accounted for 20.9% of total revenue, reflecting a 16.5% increase in international sales to $78.4 million. The company continues to focus on expanding its product offerings and market presence, particularly in the thrombectomy and embolization sectors. The company’s gross margin improved to 67.6%, up from 66.6% in the previous year, attributed to a favorable product mix and increased operational efficiencies.

Looking ahead, Penumbra anticipates continued growth driven by its innovative product portfolio and strategic initiatives, including the merger with Boston Scientific. The company remains committed to investing in research and development to enhance its product offerings and expand its market reach, while also managing operational costs effectively to improve profitability.